Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Revenue: 2009-2024

Historic Revenue for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $167.1 million.

  • Ligand Pharmaceuticals' Revenue rose 122.85% to $115.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.2 million, marking a year-over-year increase of 64.83%. This contributed to the annual value of $167.1 million for FY2024, which is 27.28% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Revenue of $167.1 million as of FY2024, which was up 27.28% from $131.3 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Revenue ranged from a high of $241.5 million in FY2021 and a low of $131.3 million during FY2023.
  • Moreover, its 3-year median value for Revenue was $167.1 million (2024), whereas its average is $164.9 million.
  • In the last 5 years, Ligand Pharmaceuticals' Revenue surged by 47.68% in 2021 and then tumbled by 33.09% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Revenue (Yearly) stood at $163.6 million in 2020, then soared by 47.68% to $241.5 million in 2021, then declined by 18.75% to $196.2 million in 2022, then tumbled by 33.09% to $131.3 million in 2023, then rose by 27.28% to $167.1 million in 2024.